Qiagen N.V. $QGEN Shares Purchased by Capital International Investors

Capital International Investors raised its stake in shares of Qiagen N.V. (NYSE:QGEN) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,587,505 shares of the company’s stock after buying an additional 264,412 shares during the period. Capital International Investors owned approximately 1.23% of Qiagen worth $116,361,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of QGEN. 111 Capital bought a new position in shares of Qiagen during the 4th quarter valued at about $776,000. Nuance Investments LLC boosted its position in shares of Qiagen by 49.1% during the 4th quarter. Nuance Investments LLC now owns 803,588 shares of the company’s stock valued at $36,137,000 after purchasing an additional 264,767 shares in the last quarter. Transatlantique Private Wealth LLC bought a new position in shares of Qiagen during the 4th quarter valued at about $562,000. Natixis Advisors LLC boosted its position in shares of Qiagen by 7.9% during the 4th quarter. Natixis Advisors LLC now owns 1,411,746 shares of the company’s stock valued at $63,486,000 after purchasing an additional 103,049 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Qiagen by 1.8% during the 4th quarter. BNP Paribas Financial Markets now owns 1,179,437 shares of the company’s stock valued at $53,039,000 after purchasing an additional 20,579 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Down 1.1%

NYSE:QGEN opened at $36.28 on Tuesday. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The firm has a market cap of $7.48 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 3.65 and a beta of 0.66. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $37.26 and its 200-day moving average is $44.31.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting analysts’ consensus estimates of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The company had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. During the same quarter last year, the firm posted $0.56 earnings per share. Equities analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s dividend payout ratio is presently 13.61%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $43.00 target price on shares of Qiagen in a report on Thursday, April 30th. Citigroup reiterated a “hold” rating on shares of Qiagen in a report on Monday, May 18th. Finally, Weiss Ratings cut shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Qiagen currently has an average rating of “Hold” and a consensus price target of $44.98.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.